The Rays are still Shining: SRAY SP

2nd Quarter Results Review [6 months ending 30th Sept, 04 vs 03]

• Revenue: +19.4%
  
• Profit after tax: + 13.6%
  
• Net Cash Flow from Operations: +133.5%
  
• Cash and Cash Equivalents at end of Period: +729.6%
  
• EPS: 8.57 cents RMB [-12.9%] on a weighted average number of shares of 304,246,880
  
• NAV per ordinary share: 44.46 cents RMB [-6.8%]
  

Future Outlook

• To launch new product: Bio feedback therapy apparatus in second half of FY2005;
  
• Acquired a subsidiary [Grand Most Ltd] which is principally engaged in trading of German O&G equipment;
  
• Also has the rights to some American O&G medical equipment;
  
• Fetal monitoring apparatus has obtained CE mark;Getting O&G medical apparatus registered with US FDA.